MKL-1 Xenograft Model Overview

The MKL-1 xenograft model is derived from a human malignant peripheral nerve sheath tumor (MPNST) cell line, MKL-1, established from a primary tumor of a patient diagnosed with neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumor. MPNST is a rare and aggressive soft tissue sarcoma that arises from peripheral nerves, and it is strongly associated with NF1, a genetic disorder that predisposes individuals to various benign and malignant tumors. The MKL-1 xenograft model is valuable for studying the biology of MPNST, the molecular mechanisms driving tumor progression, metastasis, and resistance to chemotherapy, as well as evaluating novel therapeutic strategies for treating MPNST and NF1-associated tumors.

Request a Custom Quote for MKL-1 Xenograft Model

Biological and Molecular Characteristics

MKL-1 cells exhibit several features typical of MPNST, including a high degree of cellular pleomorphism, spindle cell morphology, and strong expression of markers associated with nerve sheath differentiation, such as S100, p75 neurotrophin receptor (p75NTR), and glial fibrillary acidic protein (GFAP). MKL-1 cells also harbor mutations in the NF1 gene, which results in loss of neurofibromin, a tumor suppressor protein that negatively regulates the RAS/MAPK signaling pathway. The loss of neurofibromin contributes to aberrant activation of RAS and downstream signaling, driving tumorigenesis and increasing the risk of malignant transformation. Additionally, MKL-1 cells exhibit dysregulated signaling in pathways such as PI3K/AKT, MAPK/ERK, and mTOR, which are involved in cell survival, proliferation, and metastasis. These molecular alterations make the MKL-1 xenograft model an ideal platform for studying targeted therapies that aim to inhibit these pathways.

Marker	Expression Level	Function
S100	High	Nerve sheath differentiation marker
p75NTR	Elevated	Neurotrophin receptor involved in tumor growth
NF1	Mutated	Tumor suppressor gene involved in RAS regulation
PI3K/AKT pathway	Dysregulated	Promotes cell survival and proliferation

In Vivo Model Development and Tumorigenicity

The MKL-1 xenograft model is typically established by implanting MKL-1 cells into immunocompromised mice, such as NOD/SCID or NSG mice, which lack functional T and B cells. Once implanted, the cells form rapidly growing tumors that closely resemble human MPNST in terms of morphology, growth patterns, and metastasis. These tumors exhibit high cellularity, spindle cell morphology, and significant vascularization, reflecting the angiogenic properties of the tumor. MKL-1 xenografts are useful for evaluating the effects of chemotherapy agents commonly used in the treatment of soft tissue sarcomas, such as doxorubicin, ifosfamide, and cisplatin.

In addition to subcutaneous implantation, orthotopic models of MKL-1 can be established by implanting the cells into peripheral nerve tissues or soft tissues of immunocompromised mice. This orthotopic model more accurately replicates the natural site of tumor growth and allows for the study of local invasion, metastatic spread, and the effects of treatment on the tumor microenvironment. MKL-1 xenografts are capable of metastasizing to distant organs, particularly the lungs and lymph nodes, making this model highly relevant for studying metastatic disease and evaluating therapies aimed at preventing or treating metastasis in MPNST.

Request a Custom Quote for MKL-1 Xenograft Model

Histopathology and Immunohistochemical Profile

Histopathological examination of MKL-1 xenografts reveals the characteristic features of MPNST, including spindle-shaped tumor cells with high mitotic activity, pleomorphism, and areas of necrosis. Immunohistochemical staining of MKL-1 xenografts shows strong expression of S100, p75NTR, and GFAP, confirming the nerve sheath origin of the tumor. Additionally, the loss of neurofibromin is evident in MKL-1 xenografts, which is consistent with the NF1 mutation present in the cells. The tumors also exhibit elevated levels of phosphorylated AKT and ERK, indicating activation of the PI3K/AKT and MAPK/ERK signaling pathways, both of which contribute to tumor growth and survival. CD31 staining reveals significant angiogenesis within the tumors, highlighting the importance of blood vessel formation in supporting tumor growth.

Preclinical Applications and Drug Response

The MKL-1 xenograft model is widely used to evaluate the efficacy of various therapeutic agents for MPNST. The model is particularly useful for testing chemotherapy agents such as doxorubicin, ifosfamide, and cisplatin, which are commonly used in the treatment of soft tissue sarcomas, including MPNST. Given its potential for developing resistance to chemotherapy, the MKL-1 xenograft model is highly valuable for studying chemotherapy resistance mechanisms and for testing new agents aimed at overcoming these challenges.

The MKL-1 xenograft model is also useful for evaluating targeted therapies that inhibit dysregulated signaling pathways, particularly those involving the RAS/MAPK and PI3K/AKT pathways. Inhibition of these pathways can reduce tumor growth, enhance sensitivity to chemotherapy, and block metastasis. Additionally, the model is increasingly used to assess the potential of immunotherapies, including immune checkpoint inhibitors, which are showing promise in treating other cancers and are now being explored for MPNST and NF1-associated tumors.

Furthermore, the MKL-1 xenograft model can be used to investigate combination therapies that include chemotherapy agents and novel targeted treatments. The model’s ability to replicate the features of MPNST, including its aggressive growth, metastasis, and resistance to therapy, makes it an ideal platform for studying new treatment strategies. Moreover, MKL-1 tumors provide a valuable system for studying tumor microenvironment interactions and evaluating therapies that modulate immune responses and tumor vasculature.

Request This Model

To request the MKL-1 xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for MKL-1 Xenograft Model